|
MMP9 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.855440E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.866600E-01 |
| Normal-vs-Stage2 |
2.222000E-01 |
| Normal-vs-Stage3 |
9.828100E-02 |
| Normal-vs-Stage4 |
2.412500E-02 |
| Stage1-vs-Stage2 |
1.292160E-02 |
| Stage1-vs-Stage3 |
2.577800E-01 |
| Stage1-vs-Stage4 |
6.070400E-02 |
| Stage2-vs-Stage3 |
5.863700E-03 |
| Stage2-vs-Stage4 |
1.703010E-03 |
| Stage3-vs-Stage4 |
4.068400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.388000E-02 |
| Normal-vs-AfricanAmerican |
5.935000E-01 |
| Normal-vs-Asian |
4.994600E-01 |
| Caucasian-vs-AfricanAmerican |
7.518200E-01 |
| Caucasian-vs-Asian |
2.630000E-01 |
| AfricanAmerican-vs-Asian |
8.491600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.401950E-01 |
| Normal-vs-Female |
3.386200E-01 |
| Male-vs-Female |
3.940200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.225000E-01 |
| Normal-vs-Age(41-60Yrs) |
4.712400E-01 |
| Normal-vs-Age(61-80Yrs) |
2.433800E-01 |
| Normal-vs-Age(81-100Yrs) |
2.648200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.318000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.121000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.248800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.438800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.006800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.320800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.234800E-01 |
| Classical-VS-Follicular |
4.6074255521944E-14 |
| Classical-VS-Other |
2.659800E-02 |
| Classical-VS-Normal |
3.863800E-02 |
| Tall-VS-Follicular |
2.438200E-04 |
| Tall-VS-Other |
1.501550E-01 |
| Tall-VS-Normal |
1.614200E-01 |
| Follicular-VS-Other |
3.103600E-01 |
| Follicular-VS-Normal |
5.060900E-03 |
| Other-VS-Normal |
5.336600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.392000E-01 |
| Normal-vs-N1 |
1.591230E-01 |
| N0-vs-N1 |
2.133400E-01 |
|
|
